Kestra Appoints Timothy Moran as Chief Business Officer, Strengthening Leadership Team for Next Stage of Growth
Kestra Medical Technologies (Nasdaq: KMTS) appointed Timothy Moran as Chief Business Officer, effective November 3, 2025. In the role Moran will lead business strategy, corporate business development, payor engagement and contracting, reimbursement strategy, and revenue cycle management.
Moran brings over 25 years in medtech, most recently serving as president and CEO at Avertix Medical where he led a launch of a first‑to‑market implantable cardiac device, and previously as CEO of Motus GI Holdings. Management expects Moran to support the company’s commercial ramp, advance payor and provider partnerships, and accelerate adoption of the Cardiac Recovery System and ASSURE® WCD.
Kestra Medical Technologies (Nasdaq: KMTS) ha nominato Timothy Moran come Chief Business Officer, con effetto 3 novembre 2025. Nel ruolo Moran guiderà strategia aziendale, sviluppo aziendale corporativo, coinvolgimento e contrattazione con i payor, strategia di rimborsazione e gestione del ciclo di ricavi.
Moran porta oltre 25 anni nel settore medtech, più recentemente ricoprendo il ruolo di presidente e CEO presso Avertix Medical dove ha guidato il lancio di un dispositivo cardiaco impiantabile primo sul mercato, e in precedenza come CEO di Motus GI Holdings. Si prevede che Moran supporti la crescita commerciale della società, avanzando le partnership con payor e fornitori e accelerando l’adozione del Cardiac Recovery System e ASSURE® WCD.
Kestra Medical Technologies (Nasdaq: KMTS) nombró a Timothy Moran como Chief Business Officer, con efecto el 3 de noviembre de 2025. En el puesto Moran dirigirá la estrategia comercial, desarrollo corporativo, relación con pagadores y contratos, estrategia de reembolso y gestión del ciclo de ingresos.
Moran aporta más de 25 años en medtech, habiendo sido presidente y CEO en Avertix Medical, donde lideró el lanzamiento de un dispositivo cardíaco implantable de primer mercado, y previamente CEO de Motus GI Holdings. Se espera que Moran apoye la aceleración comercial de la empresa, fortalezca las asociaciones con pagadores y proveedores y acelere la adopción del Cardiac Recovery System y ASSURE® WCD.
Kestra Medical Technologies (Nasdaq: KMTS)가 Timothy Moran을 Chief Business Officer로 임명했고, 효력은 2025년 11월 3일부터입니다. Moran은 이 직무에서 비즈니스 전략, 기업 비즈니스 개발, 보험자가맹 및 계약, 상환 전략, 매출 주기 관리 등을 주도합니다.
Moran은 25년이 넘는 메드테크 경력을 보유하고 있으며, 최근 Avertix Medical의 사장 겸 CEO로 재임하며 시판 최초의 이식 가능한 심장 기기의 출시를 주도했고, 이전에는 Motus GI Holdings의 CEO로 재직했습니다. 경영진은 Moran이 회사의 상업적 확대를 지원하고 보험자 및 제공자 파트너십을 강화하며 Cardiac Recovery System 및 ASSURE® WCD의 채택을 가속화할 것으로 기대합니다.
Kestra Medical Technologies (Nasdaq: KMTS) a nommé Timothy Moran au poste de Chief Business Officer, à compter du 3 novembre 2025. Dans ce rôle, Moran dirigera la stratégie commerciale, le développement commercial d’entreprise, l’engagement et la contractualisation avec les payeurs, la stratégie de remboursement et la gestion du cycle des revenus.
Moran apporte plus de 25 ans d’expérience dans le medtech, ayant récemment été président et PDG d’Avertix Medical, où il a dirigé le lancement d’un dispositif cardiaque implantable premier sur le marché, et auparavant PDG de Motus GI Holdings. La direction s’attend à ce que Moran soutienne la montée en puissance commerciale de l’entreprise, fasse progresser les partenariats avec payeurs et prestataires et accélère l’adoption du Cardiac Recovery System et ASSURE® WCD.
Kestra Medical Technologies (Nasdaq: KMTS) hat Timothy Moran zum Chief Business Officer ernannt, mit Wirkung zum 3. November 2025. In dieser Rolle wird Moran die Geschäftsstrategie, die Unternehmensentwicklung, Verhandlungen mit Kostenträgern und Verträge, Erstattungsstrategie und das Revenue-Cycle-Management leiten.
Moran bringt über 25 Jahre Erfahrung in der Medizintechnik mit, zuletzt als Präsident und CEO von Avertix Medical, wo er die Markteinführung eines erstmarktfähigen implantierbaren kardialen Geräts leitete, zuvor war er CEO von Motus GI Holdings. Die Geschäftsführung erwartet, dass Moran das kommerzielle Hochlaufen des Unternehmens unterstützt, Partnerschaften mit Kostenträgern und Anbietern vorantreibt und die Einführung des Cardiac Recovery System sowie ASSURE® WCD beschleunigt.
أعلنت Kestra Medical Technologies (بورصة ناسداك: KMTS) عن تعيين تيموثي موران في منصب Chief Business Officer، على أن يبدأ ≪إعتباراً من≫ 3 نوفمبر 2025. في هذا الدور سيقود موران استراتيجيات الأعمال، وتطوير الأعمال المؤسسية، ومشاركة ودعم علاقات مع دافعي التكاليف، واستراتيجية السداد، وإدارة دورة الإيرادات.
يجلب موران أكثر من 25 عاماً من الخبرة في التكنولوجيا الطبية، حيث شغل مؤخراً منصب رئيس مجلس الإدارة والرئيس التنفيذي في Avertix Medical وقاد إطلاق أول جهاز قلب قابل للزرع في السوق، وكان سابقاً الرئيس التنفيذي لشركة Motus GI Holdings. تتوقع الإدارة أن يدعم موران النمو التجاري للشركة، وأن يعزز الشراكات مع الدافعين والموردين، وأن يسرع اعتماد Cardiac Recovery System و ASSURE® WCD.
Kestra Medical Technologies (纳斯达克: KMTS) 任命 Timothy Moran 为首席业务官，任期自 2025 年 11 月 3 日 起生效。在此职位上，Moran 将领导商业策略、企业业务发展、与付款方的参与及合同、报销策略以及收入周期管理。
Moran 拥有超过 25 年 的医疗科技行业经验，最近任职于 Avertix Medical 担任总裁兼 CEO，领导推出了首个上市的可植入心脏设备；在此之前，他曾任 Motus GI Holdings 的 CEO。管理层预计 Moran 将支持公司的商业扩张、推动与付款方及提供方的伙伴关系，并加速 Cardiac Recovery System 与 ASSURE® WCD 的采用。
- Appointment effective Nov 3, 2025 adds senior commercial leadership
- 25+ years of medtech experience brings sector expertise
- Direct experience launching a first‑to‑market cardiac device
- Mandate includes payor contracting and reimbursement strategy
- None.
KIRKLAND, Wash., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Timothy Moran as Chief Business Officer, effective November 3. In this role, Mr. Moran will oversee business strategy, corporate business development, payor engagement and contracting, reimbursement strategy, and revenue cycle management.
“I am pleased to welcome Tim as our Chief Business Officer,” said Brian Webster, President and Chief Executive Officer of Kestra Medical Technologies. “With extensive expertise in cardiac and heart failure innovation, Tim is well positioned to join Kestra at this important stage in our commercial ramp. We expect he will help Kestra advance our payor and provider partnerships, accelerate adoption of the Cardiac Recovery System® platform, and further expand and develop our business strategy.”
Mr. Moran is a seasoned operating executive who brings over 25 years of experience in medtech organizations to his new role at Kestra. Most recently, he served as President and Chief Executive Officer at Avertix Medical where he led the launch of a first-to-market implantable cardiac device for the detection of acute coronary syndrome events. Prior to that, he was the Chief Executive Officer of Motus GI Holdings, a medical technology company focused on improving endoscopic outcomes and experiences.
“I’m excited to join Kestra at such a pivotal time in the organization’s growth,” said Mr. Moran. “Kestra’s commitment to innovation and patient protection aligns with my passion for building organizations that drive meaningful impact in healthcare. I look forward to working with our payor partners, physicians, and the Kestra team to extend the reach of the ASSURE® WCD and the broader Cardiac Recovery System platform so more patients can benefit from proven protection and comprehensive recovery support.”
About Kestra
Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com.
Media contact Rhiannon Pickus rhiannon.pickus@kestramedical.com Investor contact Neil Bhalodkar neil.bhalodkar@kestramedical.com
FAQ
When does Timothy Moran start as Kestra Chief Business Officer (KMTS)?
What responsibilities will the new Kestra CBO hold at KMTS?
How does Timothy Moran's background relate to Kestra's commercial goals?
What products will Moran focus on at Kestra (KMTS)?
Did Kestra disclose financial targets or payor agreements tied to the hire?
